Cargando…
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
Evasion from drug-induced apoptosis is a crucial mechanism of cancer treatment resistance. The proapoptotic protein NOXA marks an aggressive pancreatic ductal adenocarcinoma (PDAC) subtype. To identify drugs that unleash the death-inducing potential of NOXA, we performed an unbiased drug screening e...
Autores principales: | Doffo, Josefina, Bamopoulos, Stefanos A., Köse, Hazal, Orben, Felix, Zang, Chuanbing, Pons, Miriam, den Dekker, Alexander T., Brouwer, Rutger W. W., Baluapuri, Apoorva, Habringer, Stefan, Reichert, Maximillian, Illendula, Anuradha, Krämer, Oliver H., Schick, Markus, Wolf, Elmar, van IJcken, Wilfred F. J., Esposito, Irene, Keller, Ulrich, Schneider, Günter, Wirth, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892327/ https://www.ncbi.nlm.nih.gov/pubmed/35197278 http://dx.doi.org/10.1073/pnas.2105691119 |
Ejemplares similares
-
Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers
por: Illendula, Anuradha, et al.
Publicado: (2016) -
NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor
por: Ashry, Ramy, et al.
Publicado: (2023) -
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
por: Zhou, Nan, et al.
Publicado: (2019) -
Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma
por: Dengler, M A, et al.
Publicado: (2014) -
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
por: Hornung, Roman, et al.
Publicado: (2018)